---
layout: default
title: Colistin
parent: 僅模型預測 (L5)
nav_order: 86
evidence_level: L5
indication_count: 10
---

# Colistin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Colistin: From Multidrug-Resistant Gram-Negative Infections to Postinfectious Vasculitis

## One-Sentence Summary

Colistin (Polymyxin E) is a last-resort antibiotic clinically established for the treatment of serious infections caused by multidrug-resistant (MDR) Gram-negative bacteria, particularly carbapenem-resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae*.
The TxGNN model predicts it may be effective for **Postinfectious Vasculitis**, however there are currently **no clinical trials** and **no publications** supporting this direction.
Evidence is currently classified at the lowest tier (**L5**), and the overall recommendation is **Hold**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Last-line treatment for MDR Gram-negative bacterial infections (carbapenem-resistant organisms; derived from clinical context — no Philippines license on file) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on known pharmacology, Colistin is a polymyxin-class cationic antibiotic that exerts its antibacterial effect by binding to the lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. It has no known direct immunomodulatory mechanism and does not target eukaryotic cells or immune complexes.

Postinfectious vasculitis is an inflammatory condition of blood vessel walls that can be triggered by bacterial infections, typically through immune complex deposition, complement activation, or persistent microbial antigen stimulation following Gram-negative bacteremia. The theoretical rationale for this TxGNN prediction is that effective eradication of the underlying Gram-negative bacterial trigger — precisely Colistin's domain of activity — could prevent or reduce the antigenic load that initiates the vasculitic cascade.

However, this mechanistic link is biologically speculative. Vasculitis is an immune-mediated disease whose pathology unfolds after the infectious trigger is already present; antibiotic therapy at the post-infectious stage has no established therapeutic role. Furthermore, Colistin carries well-documented nephrotoxicity and neurotoxicity risks, making the risk-benefit profile unfavorable for an indication with no direct supporting evidence. The high TxGNN score most likely reflects an indirect graph-path connection between "Gram-negative infection" and "vascular inflammation" nodes within the knowledge graph, rather than a genuine mechanistic or clinical signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Colistin in Postinfectious Vasculitis.

---

## Literature Evidence

Currently no related literature available for Colistin in Postinfectious Vasculitis.

---

## Philippines Market Information

Colistin is currently **not registered** with the FDA Philippines and has no authorized product licenses. There are no approved products on the Philippine market. Any clinical use would require special compassionate use authorization or import permits through the appropriate regulatory channel.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Colistin is broadly recognized in clinical practice for significant nephrotoxicity (acute kidney injury) and neurotoxicity (peripheral and central neurological effects). These risks are especially relevant in critically ill patients with pre-existing renal impairment. Safety data specific to the postinfectious vasculitis indication is entirely absent, which further supports a Hold decision pending basic risk characterization.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite the TxGNN model assigning a high numeric score (99.91%), there is zero clinical or preclinical evidence supporting Colistin in postinfectious vasculitis (Evidence Level L5). The mechanistic connection is indirect and biologically uncertain, and Colistin's established nephrotoxic and neurotoxic profile creates an unfavorable risk-benefit ratio for pursuing this indication without foundational evidence.

**To proceed, the following is needed:**
- Preclinical (in vitro / animal model) studies exploring Colistin's effect on immune complex-mediated or post-infectious vascular inflammation
- Systematic literature review on antibiotic therapy in postinfectious vasculitis to establish any therapeutic precedent in the broader drug class
- MOA data retrieval from DrugBank (DG002) to determine whether any secondary pharmacological properties of Colistin (e.g., LPS neutralization, immunomodulation) could mechanistically support this indication
- TFDA/package insert safety review (DG001) to complete S1-level safety gating before any clinical hypothesis is formed
- Regulatory assessment of compassionate use pathways in the Philippines for an unregistered drug in a rare indication

---

> ⚠️ **YMYL Disclaimer:** This report is generated for **research reference purposes only** and does not constitute medical advice. Drug repurposing candidates require rigorous clinical validation before therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

